Follicular dendritic cell sarcoma treated with a variety of chemotherapy.

Abstract

Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed. The present case had a very poor prognostic disease but survived for a long time with a good performance status because of the multiple chemotherapy regimens, which follow therapeutic strategies for malignant lymphoma and soft tissue sarcoma. As far as we know, this is the first study reporting the indication of bendamustine for FDCS patients.

• Authors: Masaoki Sasaki, Hiroaki Izumi, Takaaki Yokoyama, Motohiro Kojima, Ako Hosono
• Journal: Hematological oncology (Hematol Oncol) Vol. 35 Issue 4 Pg. 905-908 (Dec 2017) ISSN: 1099-1069 [Electronic] England
• PMID: 27734516 (Publication Type: Case Reports)
• Copyright: © 2016 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.

Topics

• Adult
• Dendritic Cell Sarcoma, Follicular (drug therapy, mortality, pathology)
• Female
• Humans
• Prognosis